GlaxoSmithKline Passes On Option For Exelixis’ XL647 Lung Cancer Candidate
This article was originally published in The Pink Sheet Daily
Executive Summary
Exelixis says it will move aggressively to advance EGFR candidate into pivotal trials in first half of 2008 for NSCLC and Phase II for other cancers.
You may also be interested in...
Exelixis, GSK Deal Comes To A ‘Natural, Positive End’
GSK got what it came for, Exelixis’ CEO tells “The Pink Sheet” DAILY.
Exelixis, GSK Deal Comes To A ‘Natural, Positive End’
GSK got what it came for, Exelixis’ CEO tells “The Pink Sheet” DAILY.
GSK Selects Exelixis’ Phase II MET Inhibitor XL880
XL880 is first compound to be selected by GSK under collaboration that allows U.K. drug maker to choose three of 12 Exelixis candidates.